NCT05583110
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05583110
Title Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer (TrasTUCAN)
Acronym TrasTUCAN
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Spanish Breast Cancer Research Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP


No variant requirements are available.